X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection after antibiotic treatment.
Lead Product(s): Rbx2660
Therapeutic Area: Infections and Infectious Diseases Product Name: RBX2660
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
RBX2660 results demonstrated statistical significance with a 98.6% posterior probability of superiority, which exceeded the 97.5% minimum threshold.
Lead Product(s): Microbiota-based live biotherapeutic
Therapeutic Area: Infections and Infectious Diseases Product Name: RBX2660
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Ferring Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2021
Details:
The clinical development program for RBX2660 is the largest and most robust ever conducted in the field of microbiome-based therapeutics, including six clinical trials enrolling more than 1,000 patients to date.
Lead Product(s): Rbx2660
Therapeutic Area: Infections and Infectious Diseases Product Name: RBX2660
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Ferring Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2021
Details:
RBX2660 is an investigational, non-antibiotic, microbiome-based therapy, developed to reduce Clostridioides difficile infection recurrences currently under an ongoing pivotal Phase 3 clinical trial.
Lead Product(s): Rbx2660
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2020
Details:
Largest randomized, double-blinded study, with over 300 patients enrolled aimed to demonstrate the potential benefit of RBX2660 in reducing rates C. diff infection.
Lead Product(s): Rbx2660
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
